| Date | Time | Source | Headline | Symbol | Company |
| 09/20/2024 | 4:20PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/20/2024 | 4:15PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/20/2024 | 9:25AM | PR Newswire (US) | Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/18/2024 | 8:40AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/18/2024 | 8:35AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/18/2024 | 8:30AM | PR Newswire (US) | Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/18/2024 | 8:30AM | PR Newswire (US) | Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/11/2024 | 8:40AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/11/2024 | 8:35AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/11/2024 | 8:30AM | PR Newswire (US) | Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/09/2024 | 4:10PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/09/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/09/2024 | 8:30AM | PR Newswire (US) | Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/03/2024 | 5:25PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 09/03/2024 | 5:20PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 08/19/2024 | 9:10AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 08/19/2024 | 9:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 08/19/2024 | 9:00AM | PR Newswire (US) | TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 08/14/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 08/12/2024 | 5:01PM | Edgar (US Regulatory) | Form S-4/A - Registration of securities, business combinations: [Amend] | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 08/08/2024 | 5:30PM | Edgar (US Regulatory) | Form S-4/A - Registration of securities, business combinations: [Amend] | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 07/19/2024 | 5:03PM | Edgar (US Regulatory) | Form S-4/A - Registration of securities, business combinations: [Amend] | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 07/12/2024 | 5:17PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 07/08/2024 | 6:45AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 07/08/2024 | 6:40AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 07/08/2024 | 6:30AM | PR Newswire (US) | TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 07/01/2024 | 8:35AM | PR Newswire (US) | Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 06/13/2024 | 4:10PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 06/13/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
| 06/03/2024 | 8:50AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |